Harm Reduction: A Missing Piece to the Holistic Care of Patients Who Inject Drugs

被引:1
作者
Nolan, Nathanial S. [1 ,2 ,6 ]
Francis, Sarah M. Fracasso [3 ]
Marks, Laura R. [2 ]
Beekmann, Susan E. [4 ]
Polgreen, Philip M. [4 ]
Liang, Stephen Y. [2 ,5 ]
Durkin, Michael J. [2 ]
机构
[1] VA St Louis Hlth Care, Div Infect Dis, St Louis, MO USA
[2] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Carver Coll Med, Div Infect Dis, Iowa City, IA USA
[5] Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO USA
[6] VA St Louis Hlth Care, Div Infect Dis, JC-111,915 N Grand Blvd, St Louis, MO 63106 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 08期
关键词
harm reduction; patients who inject drugs; substance use disorder; HIV-INFECTION; PREEXPOSURE PROPHYLAXIS; UNITED-STATES; HEPATITIS-C; OXYMORPHONE; INDIANA; PEOPLE;
D O I
10.1093/ofid/ofad402
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The rise in injection drug use (IDU) has led to an increase in drug-related infections. Harm reduction is an important strategy for preventing infections among people who inject drugs (PWID). We attempted to evaluate the harm reduction counseling that infectious diseases physicians provide to PWID presenting with infections. Methods An electronic survey was distributed to physician members of the Emerging Infections Network to inquire about practices used when caring for patients with IDU-related infections. Results In total, 534 ID physicians responded to the survey. Of those, 375 (70%) reported routinely caring for PWID. Most respondents report screening for human immunodeficiency virus (HIV) and viral hepatitis (98%) and discussing the risk of these infections (87%); 63% prescribe immunization against viral hepatitis, and 45% discuss HIV preexposure prophylaxis (PrEP). However, 55% of respondents (n = 205) reported not counseling patients on safer injection strategies. Common reasons for not counseling included limited time and a desire to emphasize antibiotic therapy/medical issues (62%), lack of training (55%), and believing that it would be better addressed by other services (47%). Among respondents who reported counseling PWID, most recommended abstinence from IDU (72%), handwashing and skin cleansing before injection (62%), and safe disposal of needles/drug equipment used before admission (54%). Conclusions Almost all ID physicians report screening PWID for HIV and viral hepatitis and discussing the risks of these infections. Despite frequently encountering PWID, fewer than half of ID physicians provide safer injection advice. Opportunities exist to standardize harm reduction education, emphasizing safer injection practices in conjunction with other strategies to prevent infections (eg, HIV PrEP or hepatitis A virus/hepatitis B virus vaccination).
引用
收藏
页数:7
相关论文
共 42 条
  • [1] Ahmad F., PROVISIONAL DRUG OVE
  • [2] Strategies used by people who inject drugs to avoid stigma in healthcare settings
    Biancarelli, Dea L.
    Biello, Katie B.
    Childs, Ellen
    Drainoni, M.
    Salhaney, Peter
    Edeza, Alberto
    Mimiaga, Matthew J.
    Saitz, Richard
    Bazzi, Angela R.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2019, 198 : 80 - 86
  • [3] Estimated Number of People who Inject Drugs in the United States
    Bradley, Heather
    Hall, Eric W.
    Asher, Alice
    Furukawa, Nathan W.
    Jones, Christopher M.
    Shealey, Jalissa
    Buchacz, Kate
    Handanagic, Senad
    Crepaz, Nicole
    Rosenberg, Eli S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 76 (01) : 96 - 102
  • [4] Centers for Disease Control and Prevention, 2022, INT VIR HEP SURV PRE
  • [5] Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
    Choopanya, Kachit
    Martin, Michael
    Suntharasamai, Pravan
    Sangkum, Udomsak
    Mock, Philip A.
    Leethochawalit, Manoj
    Chiamwongpaet, Sithisat
    Kitisin, Praphan
    Natrujirote, Pitinan
    Kittimunkong, Somyot
    Chuachoowong, Rutt
    Gvetadze, Roman J.
    McNicholl, Janet M.
    Paxton, Lynn A.
    Curlin, Marcel E.
    Hendrix, Craig W.
    Vanichseni, Suphak
    [J]. LANCET, 2013, 381 (9883) : 2083 - 2090
  • [6] Preexposure Prophylaxis for the Prevention of HIV Infection Evidence Report and Systematic Review for the US Preventive Services Task Force
    Chou, Roger
    Evans, Christopher
    Hoverman, Adam
    Sun, Christina
    Dana, Tracy
    Bougatsos, Christina
    Grusing, Sara
    Korthuis, P. Todd
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (22): : 2214 - 2230
  • [7] Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443
  • [8] Hospital Costs of Injection Drug Use in Florida
    Coye, Austin E.
    Bornstein, Kasha J.
    Bartholomew, Tyler S.
    Li, Hua
    Wong, Stanley
    Janjua, Naveed Z.
    Tookes, Hansel E.
    St Onge, Joan E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (03) : 499 - 502
  • [9] Behavioral characteristics and injection practices associated with skin and soft tissue infections among people who inject drugs: A community-based observational study
    Dahlman, Disa
    Hakansson, Anders
    Kral, Alex H.
    Wenger, Lynn
    Ball, Elizabeth L.
    Novak, Scott P.
    [J]. SUBSTANCE ABUSE, 2017, 38 (01) : 105 - 112
  • [10] HIV Infection Investigation in a Rural Area - West Virginia, 2017
    Evans, Mary E.
    Labuda, Sarah M.
    Hogan, Vicki
    Agnew-Brune, Christine
    Armstrong, John
    Karuppiah, Amarnath Babu Periasamy
    Blankinship, Deborah
    Buchacz, Kate
    Burton, Kenya
    Cibrik, Sharon
    Hoffman, William
    Kirk, Nathan
    Lee, Chang
    McGraw, Dondeena
    Ocfemia, M. Cheryl Banez
    Panneer, Nivedha
    Reynolds, Pamela
    Rose, Bridget
    Salmon, Melinda
    Scott, Melissa
    Thompson, Antoine
    Wills, David
    Young, Sherri A.
    Gupta, Rahul
    Haddy, Loretta
    Weidle, Paul J.
    Mark-Carew, Miguella
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (08): : 257 - 258